You are here: Industry Insights > Covax

News List

G7 to share 870 million doses of COVID-19 vaccine with poorest countries europeanpharmaceuticalreview
June 17, 2021
Global leaders at the G7 summit pledged 870 million COVID-19 vaccine doses, with half to be delivered by the end of 2021, to COVAX for distribution among low- and middle-income countries.
UK to donate 100 million surplus COVID-19 vaccine doses pharmatimes
June 16, 2021
The UK government will donate at least 100 million surplus COVID-19 vaccine doses within the next year, Prime Minister Boris Johnson announced on Friday.
Countries, health partners deliberate on boosting response to COVID-19 in WHO South-East Asia Region expresspharma
June 07, 2021
The World Health Organization (WHO) convened a meeting of member countries and health partners to discuss strengthening of collective efforts to control COVID-19 spread.
Sinovac COVID-19 vaccine gets WHO validation for emergency use expresspharma
June 02, 2021
WHO’s Emergency Use Listing (EUL) is a prerequisite for COVAX Facility vaccine supply and international procurement.
Novavax postpones timelines for COVID-19 vaccine production, regulatory authorisations expresspharma
May 12, 2021
The company has repeatedly pushed back production forecasts and has struggled to access raw materials and equipment needed to make its vaccine.
WHO grants Sinopharm’s COVID-19 vaccine emergency approval pharmatimes
May 11, 2021
The World Health Organization (WHO) has approved Sinopharm’s COVID-19 vaccine for emergency use, making it the first jab developed by a non-Western company to gain this recommendation.
Russia authorises use of single-dose Covid-19 vaccine Sputnik Light pharmaceutical-technology
May 08, 2021
Sputnik Light, which is based on the human adenoviral vector platform, is the first component, a recombinant human adenovirus serotype number 26 (rAd26), of the Sputnik V Covid-19 vaccine.
Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility prnasia
May 07, 2021
Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced that it has finalized an advance purchase agreement (APA) with Gavi, the Vaccine Alliance (Gavi) for supply of its recombinant ...
$150 million made available for COVID-19 vaccine adverse event compensation scheme europeanpharmaceuticalreview
May 06, 2021
The COVAX No-fault Compensation Program will offer individuals in 92 lower-income countries and economies compensation for serious adverse events associated with COVID-19 vaccines distributed through COVAX.
Moderna receives emergency use listing from WHO for Covid-19 vaccine pharmaceutical-technology
May 06, 2021
Moderna has received emergency use listing (EUL) from the World Health Organization (WHO) for its Covid-19 vaccine to prevent the disease in individuals aged 18 years and above.

Previous page 1 2 3 4 5 6 7 8 Next page